Short report

Clinical and biochemical effects of gamma-vinyl Gaba in tardive dyskinesia

J M GAIO, P POLLAK, M HOMMEL, J PERRET
From the Clinique Neurologique, CHU Grenoble, France

SUMMARY Clinical and biochemical effects of Gamma-vinyl-Gaba (GVG) have been evaluated in a blind video-controlled study in 10 psychiatric patients (mean age 71 yr) with tardive dyskinesia. CSF free and total Gaba and homocarnosine concentrations increased from three to five fold with GVG treatment. Despite the GVG-induced biological effects on Gaba metabolism, GVG did not consistently improve tardive dyskinesia. Psychomotor side-effects occurred in older patients, who only tolerated GVG dosages of 2–4 g/day.

Tardive dyskinesia, a neurological disorder of abnormal hyperkinetic movement, is a frequent side effect of chronic administration of neuroleptic treatment. It occurs in predisposed patients, in whom it may become a persistent problem for which no entirely satisfactory treatment is known. The pathophysiology of tardive dyskinesia has not been definitively elucidated but the most widely accepted hypothesis is the development of dopamine receptor hypersensitivity of the striatum following prolonged exposure to neuroleptics. In chronically neuroleptic treated laboratory animals, the co-administration of Gabaergic agonists has been shown to prevent the occurrence of apomorphine-induced stereotypes and to inhibit neuronal dopaminergic activity. Therefore Gabaergic agonists might be effective agents to treat tardive dyskinesia in humans. Clinical trials using drugs with putative Gabaergic activity have produced mixed results. Thus, sodium valproate and baclofen have been claimed to be slightly beneficial. Muscimol and γ-acetylenic Gaba were also moderately effective but at the expense of unacceptable side effects. THIP was ineffective in tardive dyskinesia, with high doses being poorly tolerated.

Gamma-vinyl Gaba (GVG), an enzyme-activated irreversible inhibitor of Gaba-transaminase, produces large increases in brain Gaba concentrations of laboratory animals. In addition, oral administration of GVG to man produces dose-related elevation of CSF Gaba content probably reflecting increased brain Gaba levels. In a pilot single blind study with tardive dyskinesia patients, the administration of GVG reduced the hyperkinesia scores of six of nine patients without producing major side effects. Similar results were subsequently observed in several single blind placebo controlled studies. We also have carried out a single blind placebo controlled study with additional blind videotape rating of the effects of GVG in tardive dyskinesia patients. The clinical and biological effects of this treatment are reported.

Patients and methods

Ten elderly patients (55–85 years old, mean 71) hospitalised in a psychiatric institution were selected for the study. They were physically healthy and had exhibited stable tardive dyskinesia for at least 6 months prior to the study. They all gave informed consent. Relevant individual patient data are shown in the table. Five patients (Nos 2, 4, 5, 6, 9) entered the study with a concomitant neuroleptic treatment which had been maintained at the same dosage for at least the previous 3 months. The other patients had been off neuroleptic treatment for 1 to 3 years owing to their stable psychiatric condition. Two of the neuroleptic-treated patients (Nos 6, 9) were also receiving anticholinergic drugs. Neuroleptic and anticholinergic drugs dosage remained
Clinical and biochemical effects of gamma-vinyl Gaba in tardive dyskinesia

Table  Individual patient data

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Age (yr)</th>
<th>Psychiatric diagnosis</th>
<th>Duration of psychiatric illness (yr)</th>
<th>Duration of TD (yr)</th>
<th>Duration of previous neuroleptic treatment (yr)</th>
<th>Concurrent neuroleptic drug treatment</th>
<th>GVG Maximum dosage g/d</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>58</td>
<td>Residual schizophrenia</td>
<td>22</td>
<td>2</td>
<td>22</td>
<td>Propericazine 15 g/d</td>
<td>6</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>59</td>
<td>Cyclothymic disorder</td>
<td>15</td>
<td>2</td>
<td>15</td>
<td>Tiapride 600 mg/d</td>
<td>4</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>85</td>
<td>Schizophrenia</td>
<td>20</td>
<td>5</td>
<td>20</td>
<td>Thioridazine 100 mg/d</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>76</td>
<td>Atypical depression</td>
<td>6</td>
<td>3</td>
<td>6</td>
<td>Pimperlene 120 mg/d</td>
<td>6</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>81</td>
<td>Paranoia</td>
<td>10</td>
<td>9</td>
<td>10</td>
<td>Chlorpromazine 300 mg/d</td>
<td>5</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>55</td>
<td>Paranoid schizophrenia</td>
<td>35</td>
<td>1</td>
<td>9</td>
<td>Tiapride 150 mg/d</td>
<td>2</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>66</td>
<td>Paranoia</td>
<td>7</td>
<td>2</td>
<td>7</td>
<td>Tiapride 100 mg/d</td>
<td>3</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>83</td>
<td>Paranoid schizophrenia</td>
<td>20</td>
<td>7</td>
<td>20</td>
<td>Chlorpromazine 100 mg/d</td>
<td>3</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>74</td>
<td>Paranoia</td>
<td>6</td>
<td>3</td>
<td>6</td>
<td>Chlorpromazine 300 mg/d</td>
<td>5</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>72</td>
<td>Cyclothymic disorder</td>
<td>54</td>
<td>7</td>
<td>29</td>
<td>Chlorpromazine 100 mg/d</td>
<td>1</td>
</tr>
</tbody>
</table>

| Mean ± SD | 70±8 ± 11.9 | 19.5 ± 15.2 | 4.1 ± 2.7 | 16.4 ± 8.9 | 3.8 ± 1.8 |

Results

On the whole GVG had no significant effect on dyskinetic nor Parkinsonian symptoms at any dosage (fig 1). With GVG 2 g/day tardive dyskinesia scores slightly but not significantly improved. Individual data did not show any sustained improvement and a

Fig 1 Mean tardive dyskinesia and Parkinsonian scores. Scores are expressed on percentage, 100% representing the initial placebo scores. The columns represent the average of the scores of all the patients taking the same dosage. n is the number of patients for each dosage.

unchanged throughout the study. The study began with a 2 week placebo period, followed by a 6 week period of GVG, and a final 2 week placebo period during which the patients received the same daily number of tablets as during the last week of GVG treatment. GVG or placebo was given twice daily. The starting dose of GVG was 1 g/day, this dose being increased by 1 g/day each week, to a maximum of 6 g/day. Should any dosage less than 6 g/day abolish all signs of tardive dyskinesia be poorly tolerated, then that dose was maintained for the rest of the study.

Clinical evaluations

Symptoms of hyperkinesia and of Parkinsonism were recorded twice during the first week and then once weekly, with a videotape camera, at the same time of the day during a 10 minute standardised examination. 19 At the end of the study all tapes were examined by the same rater who was blind as to the treatments. The rating scale for tardive dyskinesia included the examination of 10 body regions, each scored 0 to 4 according to the severity of the symptoms. 19 The Parkinsonian symptoms were rated on 22 items also scored 0 to 4 for severity. 19

Biological evaluations

Routine safety biological tests were performed during the initial placebo period and repeated on the last day of the active treatment period. Lumbar CSF was obtained from seven consenting patients at the end of the initial placebo period and the 6-week GVG period. CSF was drawn at 8:00 am from fasting patients in the supine position. The 5th to 10th millilitres of CSF were collected as one ml fractions into tubes kept in dry ice. Each sample was immediately frozen at −70°C until analysis. Free and total Gaba, homocarnosine and GVG were assayed as previously described. 12 Blood Gaba and GVG concentrations were also analysed on the last day of the initial placebo period and once weekly during the GVG treatment period.

Statistical analysis of the effects of GVG on tardive dyskinesia and Parkinsonism was made using Newman-Keuls test for individual scores and Student's t test for global scores. Linear regression analysis was used for clinico-biological correlations.
slight Parkinsonian aggravating effect was observed in two patients (Nos 2, 4). Six patients completed the entire study. Of the four other patients, one (No 6) was withdrawn during the second placebo period because of reappearance of psychotic symptoms. Three patients stopped the study at the 6th week (No 7) 3rd week (No 9) and 2nd week (No 10) of the GVG period because of bad compliance. The maximum dosage of GVG ranged from 1 g/day to 6 g/day (mean 3.8 g/day ± 1.8). Side effects occurred in four patients (Nos 3, 4, 8, 9) consisting of bradypsychia, confusion, drowsiness and shuffling gait; all of these four patients were more than 74 years old, and two of them were slightly demented before the onset of the study. Oral GVG dosage was significantly related to serum and CSF concentrations but not to serum Gaba levels (data not shown). In all of the seven studied patients CSF concentrations of Gaba (free and total) and homocarnosine increased with GVG treatment from three to five-fold (fig 2). The increase of CSF free Gaba was proportional to the CSF GVG levels (fig 3) but did not correlate with oral treatment dosage. The elevations of free Gaba serum concentrations and CSF free Gaba concentrations were not related (p = 0.18). Standard laboratory data were not modified after GVG treatment.

Discussion

As no convenient long-term treatment is known for tardive dyskinesia using drugs acting on dopaminergic function, several studies have been performed with Gaba agonists.6–10 They produced mixed results ranging from no improvement10 to mild improvements6 7 9 and in this last case6 the improvement was generally accompanied by an increase in Parkinsonism. GVG has been reported by several centres to reduce the hyperkinetic symptoms of patients with tardive dyskinesia.14–18 This beneficial effect was not confirmed in our placebo-controlled study. There is no obvious single explanation for this discrepancy, but when the patient population and the GVG regimen are compared across studies, several points can be mentioned. The lack of effect of GVG in our study cannot simply be due to problems of compliance. Not only was the administration of the medication carefully monitored, but the biological results also show that GVG was found in the patients’ CSF and that CSF free Gaba concentrations increased proportionally to GVG CSF levels. The question of associated neuroleptic treatment was raised in a study9 where the positive effects of gamma-acyetylengenic Gaba correlated with the strength of concomitant neuroleptic treatment. In studies with GVG, however, improvement of tardive dyskinesia was observed independently from neuroleptic treatment.16–18 In the present study half of the subjects were receiving neuroleptics, and their responses were not different from those patients not on neuroleptic treatment. The major difference between our study and those pre-

---

**Fig 2** Total Gaba, free Gaba and homocarnosine CSF concentrations before and after oral GVG administration (mean dosage: 3.8 g/day) in seven dyskinetic patients.

**Fig 3** Correlation between CSF GVG concentrations and CSF free Gaba levels.
Clinical and biochemical effects of gamma-vinyl Gaba in tardive dyskinesia

Previously reported is the high mean age of our patient population. Six of our 10 patients were over 70 years old, a much larger proportion than in the other reports. This may have several consequences. It has been suggested that tardive dyskinesia is less likely to be irreversible as age increases, thus making any treatment less effective in old people.

It is possible that, since we have used a rapidly escalating schedule of GVG dosing with only one clinical evaluation of each dose, we may have missed a “therapeutic window”. In the study by Danion et al. a beneficial effect of GVG was observed at 1 g/day after 2 weeks of administration. Tammenga et al. also observed 44% mean decrease in total dyskinetic symptoms at 3 g/day. If the beneficial effect of GVG occurs with an average dose of 1–3 g/day this improvement could have been missed in our study because five patients received at least 4 or more g/day of GVG.

Gaba is the most ubiquitous of cerebral neurotransmitters involved in both neurotransmission and intermediary metabolism. The widely accepted effect of Gaba as a neurotransmitter is an inhibitory one. But in animals, studies which alter the local Gabaergic neuronal activity show different and sometimes conflicting behavioural motor modifications dependant upon the neuronal structure involved and even the exact locus inside this structure. Thus, one of the explanations of the lack of a clear clinical motor effect of GVG could be this various involvement of Gabaergic systems in the CNS.

The increase in Parkinsonism scores seen in two patients taking neuroleptics is in agreement with the results of other clinical studies. Such a hypokinetic effect is seen in rodents where Gaba agonists aggrivate neuroleptic-induced catalepsy. Additionally, it appears from this and other reports that the tolerance to GVG decreases with age. The four younger patients of our study (less than 70 years old) tolerated GVG doses up to 4–6 g/day whereas the older patients tolerated only doses of 2–4 g/day. Furthermore, the four patients of our study who presented side effects all belonged to the older patient group. Similarly, the two patients of the Korsgaard’s study who developed confusion were 70 and 78 years old; this side effect being not observed in the seven patients under 70. Therefore we may have reached the limit of tolerance in most patients without disclosing any beneficial effects of the drug.

GVG produced a three to five-fold increase in CSF concentrations of free Gaba, total Gaba and homocarnosine. These CSF increases are better related to GVG CSF levels than GVG oral dosage, favouring a direct effect of GVG on CNS. The increase in CSF Gaba probably reflects a similar increase in human brain concentrations, as has been demonstrated in rat studies. Some Gabaergic drugs can induce such modifications in CSF Gaba concentrations. Valproic acid only produces a moderate increase of 77%. Isoniazid-induced elevation of CSF Gaba is obtained with unusually high oral doses. Biological results similar to ours are found in patients with Huntington’s disease treated with γ-acetylenic Gaba, but this drug causes major side effects. Thus far, GVG appears to be the best tolerated drug capable of elevating brain Gaba concentrations. However, despite the obvious GVG-induced biological effects on the CNS Gaba system, GVG did not produce any clear benefit in an elderly group of psychiatric patients suffering from tardive dyskinesia.

We thank B Guerin for his technical assistance, and C Palao for the manuscript preparation.

Biochemical determination was carried out by the staff at Merrell Dow Research Institute, Strasbourg, France, who assume no responsibility for clinical results and discussion of this manuscript.

References

14 Tell GP, Schechter PJ, Koch-Weser J, Cantiniaux P, Chabannes
1678